- Emily Edelman, project director1,
- Charis Eng, Sondra J and Stephen R Hardis chair of cancer genomic medicine, professor and chair2
- 1National Coalition for Health Professional Education in Genetics, Lutherville, MD 21093, USA
- 2Cleveland Clinic Genomic Medicine Institute, Cleveland, OH 44195, USA
- Correspondence to: C Eng, Genomic Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, NE-50, Cleveland, OH 44195, USA engc{at}ccf.org
Summary points
Personal genomic screening is a rapidly evolving area of direct to consumer genetic testing
Such screening uses data from genome-wide association studies to predict a person’s disease risk and tests using many genetic markers at once
Companies may offer genomic testing for common diseases and traits as well as rare mendelian conditions
Screening results may include predictions about physical or personality traits, pharmacogenetic profiles, and ancestry testing
Doctors should use caution when a patient presents with such screening results because their accuracy and usefulness are unknown
Instead, risk of disease should be based on validated clinical methods, such as family history and clinical and biochemical measures
Researchers are identifying genetic associations for common diseases at a rapid pace. With enormous amounts of genome-wide association data available, several for-profit companies worldwide have developed testing services to provide clients with predictions about their risks for a broad spectrum of medical and non-medical conditions and traits—from ancestry grouping, to earwax type, to prostate cancer. Many of these companies provide services direct to the consumer, without input or authorisation from a doctor or other healthcare provider.
Sources and selection criteria
Because of the various types of genetic associations analysed and the rapid evolution of tests offered by personal genomic screening companies, data on evidence based assessments of these services are limited. We searched PubMed for combinations of terms such as “direct-to-consumer”, “personal-genomic testing”, “personal-genomic profile”, “clinical utility”, “clinical validity”, and “evidence” to identify studies assessing the current state of evidence.
We searched the Genetics and Public Policy Center at Johns Hopkins University and the Human Genetics Commission’s 2007 report More Genes Direct to identify direct to consumer genetic testing companies that provide personal genomic scanning for multiple conditions. We reviewed the websites of many of the companies.
Doctors may be asked for advice on medical matters that arise …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
The decline in the breast cancer incidence is 1.2% and it is not significant.
Published 10 February 2012
'twas ever thus
Published 10 February 2012
The value of historic human remains
Published 10 February 2012
In Praise of British Literature
Published 10 February 2012
Is real shared decision making possible?
Published 10 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (7 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012
Search for evidence goes on (5 responses)
Published 17 Jan 2012